News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<IPO>AI Drug Startup Insilico Medicine Reportedly Plans to Relaunch HK IPO w/ US$1B+ Valuation
Insilico Medicine Inc., an AI-driven drug discovery startup, is contemplating rebooting its Hong Kong IPO plans following a new round of financing, Bloomberg reported. The company ...
Reset
Send
The window will close in 5 seconds
<IPO>AI Drug Startup Insilico Medicine Reportedly Plans to Relaunch HK IPO w/ US$1B+ Valuation
Close
Recommend
16
Positive
26
Negative
12
 
SHORT SELL
 
STOCK INFO

Insilico Medicine Inc., an AI-driven drug discovery startup, is contemplating rebooting its Hong Kong IPO plans following a new round of financing, Bloomberg reported. The company is anticipated to pursue a listing with a valuation exceeding USD1 billion.

In January this year, Insilico Medicine wrapped up a Series E funding round led by Value Partners Group, seizing approximately USD110 million. The round wooed investors including Warburg Pincus, OrbiMed Advisors, and Eli Lilly.

Related NewsRatings & TPs on HKEX (00388.HK) (Table)
Insilico Medicine had previously submitted Main Board listing applications to the Hong Kong Stock Exchange in June 2023 and March 2024, with Morgan Stanley and CICC serving as joint sponsors.

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.